FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293229968> ?p ?o ?g. }

• W4293229968 abstract "<h3>Background and importance</h3> Long-term dual antiplatelet therapy (DAPT) is one of the most researched therapies that involves the combination of acetylsalicylic acid (ASA) and platelet adenosine diphosphate receptor inhibitor (P2Y₁₂). The main indication for DAPT is prevention of coronary events after an acute coronary syndrome (ACS) or after a percutaneous coronary intervention (PCI) but in practice, there is confusion. Recommendations indicate that DAPT can be maintained over a year depending on the ischaemic and haemorrhagic risk of each patient. <h3>Aim and objectives</h3> The aim of this study was to investigate DAPT indications and risk factors related to extending this therapy for over a year despite the fact that suspension of one antiplatelet drug was indicated (medication discrepancies). <h3>Material and methods</h3> Of a total number of 221 patients with DAPT from January 2009–2020, this observational and reprospective study was based on a simple random sampling including 33% of the total of patients. Data were obtained by review of electronic medical records. <h3>Variables collected</h3> demographic, clinical services, DAPT indication, drugs used, durability, risk factors of extending DAPT and medication discrepancies. <h3>Results</h3> Final analyses included 70 patients. Median age 69 (IQR 63–78) years, 88.6% men. The median of years with DAPT was 6.5 (IQR 3–11). The prescribing clinical services were cardiology (84.3%), vascular surgery (5.7%) and others (10%). Patients treated with ASA+clopidogrel were 87.1%, 10% with ASA+ticagrelor and 2.9% others. Of the 70 patients studied, 91.4% had indications for use of DAPT therapy and 8.6% did not. According to therapeutic indication, 61.4% had ACS and PCI and 30% had stable coronary artery disease and PCI. Among patients without indication, 4.3% were treated for conservative management of ACS and 4.3% for stroke prevention. Risk factors that may justify long-term therapy were: 40% previous acute myocardial infarction, 34.3% multivessel coronary artery disease, 10% recurrent ischemic events and others. 8.6% of patients had medication discrepancies. <h3>Conclusion and relevance</h3> Many patients had indication for DAPT at the beginning of treatment and had risk factors that would justify long-term DAPT but duration was not evaluated. It is necessary for a multidisciplinary team to manage this therapy, considering the risk–benefit to each patient. <h3>References and/or acknowledgements</h3> <h3>Conflict of interest</h3> No conflict of interest" @default.
• W4293229968 created "2022-08-27" @default.
• W4293229968 creator A5016682079 @default.
• W4293229968 creator A5023780709 @default.
• W4293229968 creator A5036351505 @default.
• W4293229968 creator A5050036430 @default.
• W4293229968 creator A5087502126 @default.
• W4293229968 date "2022-03-01" @default.
• W4293229968 modified "2023-09-28" @default.
• W4293229968 title "5PSQ-087 Long-term dual antiplatelet therapy: controversy continues" @default.
• W4293229968 doi "https://doi.org/10.1136/ejhpharm-2022-eahp.309" @default.
• W4293229968 hasPublicationYear "2022" @default.
• W4293229968 type Work @default.
• W4293229968 citedByCount "0" @default.
• W4293229968 crossrefType "proceedings-article" @default.
• W4293229968 hasAuthorship W4293229968A5016682079 @default.
• W4293229968 hasAuthorship W4293229968A5023780709 @default.
• W4293229968 hasAuthorship W4293229968A5036351505 @default.
• W4293229968 hasAuthorship W4293229968A5050036430 @default.
• W4293229968 hasAuthorship W4293229968A5087502126 @default.
• W4293229968 hasBestOaLocation W42932299681 @default.
• W4293229968 hasConcept C126322002 @default.
• W4293229968 hasConcept C164705383 @default.
• W4293229968 hasConcept C23131810 @default.
• W4293229968 hasConcept C2777628954 @default.
• W4293229968 hasConcept C2777698277 @default.
• W4293229968 hasConcept C2777849778 @default.
• W4293229968 hasConcept C2780400711 @default.
• W4293229968 hasConcept C2780890252 @default.
• W4293229968 hasConcept C2909112448 @default.
• W4293229968 hasConcept C45393284 @default.
• W4293229968 hasConcept C500558357 @default.
• W4293229968 hasConcept C71924100 @default.
• W4293229968 hasConceptScore W4293229968C126322002 @default.
• W4293229968 hasConceptScore W4293229968C164705383 @default.
• W4293229968 hasConceptScore W4293229968C23131810 @default.
• W4293229968 hasConceptScore W4293229968C2777628954 @default.
• W4293229968 hasConceptScore W4293229968C2777698277 @default.
• W4293229968 hasConceptScore W4293229968C2777849778 @default.
• W4293229968 hasConceptScore W4293229968C2780400711 @default.
• W4293229968 hasConceptScore W4293229968C2780890252 @default.
• W4293229968 hasConceptScore W4293229968C2909112448 @default.
• W4293229968 hasConceptScore W4293229968C45393284 @default.
• W4293229968 hasConceptScore W4293229968C500558357 @default.
• W4293229968 hasConceptScore W4293229968C71924100 @default.
• W4293229968 hasLocation W42932299681 @default.
• W4293229968 hasOpenAccess W4293229968 @default.
• W4293229968 hasPrimaryLocation W42932299681 @default.
• W4293229968 hasRelatedWork W1985989850 @default.
• W4293229968 hasRelatedWork W2019045182 @default.
• W4293229968 hasRelatedWork W2170949977 @default.
• W4293229968 hasRelatedWork W3039138000 @default.
• W4293229968 hasRelatedWork W3110571006 @default.
• W4293229968 hasRelatedWork W3134665543 @default.
• W4293229968 hasRelatedWork W3135788989 @default.
• W4293229968 hasRelatedWork W3203361566 @default.
• W4293229968 hasRelatedWork W4205730351 @default.
• W4293229968 hasRelatedWork W4288064445 @default.
• W4293229968 isParatext "false" @default.
• W4293229968 isRetracted "false" @default.
• W4293229968 workType "article" @default.